For Many, CAR T is a Miracle Therapy – We Need to Get it to More Patients
To truly expand CAR T access and prepare for the wave of new T cell-based therapies coming through the pipeline, we must find better ways to manage CRS and ICANS.
Teresa Whalen
Teresa Whalen, RPh, is CEO of CytoAgents, a clinical-stage biotech developing novel solutions for Cytokine Release Syndrome (CRS), a life-threatening immune overreaction. With more than 20 years of experience across the healthcare industry, Teresa has served as a biotech innovator, healthcare technology leader, hospital board trustee, life sciences investor, and clinical pharmacist. She has successfully guided healthcare products from concept to market, leveraging her deep expertise in clinical development and commercialization. At CytoAgents, she leads a world-class team of drug development experts and scientific advisors advancing groundbreaking treatments that address systemic inflammation and improve patient outcomes. Teresa also serves on multiple industry boards and is passionate about translating scientific innovation into meaningful therapies that change lives.